Global Gastrointestinal Events with Celecoxib vs. Diclofenac and Omeprazole

Risks for clinical events throughout the GI tract were lower with a cyclooxygenase-2 inhibitor than with a nonselective nonsteroidal anti-inflammatory drug plus a proton-pump inhibitor.

The association between nonsteroidal anti-inflammatory drugs (NSAIDs) and upper gastrointestinal (GI) bleeding and ulceration is well documented. Such adverse events can be reduced by use of a cyclooxygenase (COX)-2 selective NSAID or a proton-pump inhibitor (PPI) with a nonselective NSAID. However, prospective trials that evaluate these strategies to prevent NSAID-related events throughout the GI tract are lacking.

To address this issue, investigators conducted an industry-sponsored trial (CONDOR), involving 4484 patients with osteoarthritis or rheumatoid arthritis from 196 centers in 32 countries. Patients were randomized to receive celecoxib (Celebrex; 200 mg twice daily) or diclofenac (75 mg twice daily) plus omeprazole (20 mg once daily…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Global Gastrointestinal Events with Celecoxib vs. Diclofenac and Omeprazole

Topics

Reviewing Author